Glenmark Strengthens U.S. Presence with New Generic Anti-Epileptic Injection
Glenmark Pharmaceuticals Ltd. has further strengthened its position in the U.S. pharmaceutical market with the launch of Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials through its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA. The product is the generic equivalent of Vimpat Injection, originally marketed by UCB Inc., and is used for the treatment of seizures associated with epilepsy.
The launch represents another important milestone in Glenmark’s strategy to expand its injectable medicines portfolio while providing healthcare providers and patients with affordable treatment alternatives in the United States.
Expanding Access to Epilepsy Treatment
Lacosamide Injection is indicated for patients experiencing seizures related to epilepsy and is commonly used in hospital and acute care settings. Glenmark’s newly introduced generic version has been approved as bioequivalent and therapeutically equivalent to the reference listed drug, ensuring the same safety, efficacy, and quality standards.
By introducing a lower-cost generic alternative, Glenmark aims to improve patient access to essential neurological treatments while helping healthcare systems manage treatment costs more effectively.
Significant Market Opportunity
According to IQVIA sales data referenced by the company, the U.S. market for Vimpat Injection generated approximately USD 15.2 million in annual sales during the twelve-month period ending April 2026.
The market size highlights a meaningful opportunity within the injectable anti-epileptic drug segment, where demand continues to be driven by the need for effective seizure management in both inpatient and emergency care environments.
As healthcare providers increasingly seek cost-efficient treatment options, generic injectable medicines remain a critical component of modern healthcare delivery.
Strategic Focus on Injectable Medicines
The launch aligns with Glenmark’s broader strategy of building a differentiated and sustainable portfolio in North America. Over the past few years, the company has increased its focus on injectable products, recognizing the growing demand for complex generics and hospital-based therapies.
Commenting on the development, Marc Kikuchi, President and Business Head, North America, stated that the introduction of Lacosamide Injection reflects Glenmark’s commitment to expanding its U.S. portfolio while addressing evolving healthcare needs.
He emphasized that strengthening the company’s injectable offerings will help improve access to quality medicines and support healthcare providers with cost-effective treatment solutions.
Strengthening Presence in the U.S. Generics Market
The United States remains one of the world’s most competitive pharmaceutical markets, particularly in the generics segment. Glenmark has steadily expanded its footprint through strategic product launches across multiple therapeutic categories.
The addition of Lacosamide Injection further enhances the company’s injectable medicine portfolio and demonstrates its ability to develop and commercialize high-quality generic alternatives for complex therapies.
As healthcare systems continue to prioritize affordability and accessibility, generic manufacturers like Glenmark play a vital role in ensuring patients receive essential medications without compromising on quality.
Looking Ahead
With the launch of Lacosamide Injection USP, Glenmark continues to reinforce its commitment to innovation, affordability, and patient access. The product not only expands the company’s injectable portfolio but also strengthens its position in the growing U.S. generics market.
As Glenmark pursues further opportunities in complex generics and injectable medicines, the company remains focused on delivering high-quality therapies that address critical healthcare needs while creating value for patients, providers, and healthcare systems alike.
Key Highlights
- Glenmark launches Lacosamide Injection USP 200 mg/20 mL in the U.S.
- Generic equivalent of Vimpat Injection by UCB Inc.
- Used for treatment of seizures associated with epilepsy.
- Bioequivalent and therapeutically equivalent to the reference product.
- U.S. market size estimated at USD 15.2 million annually.
- Strengthens Glenmark’s injectable medicines portfolio.
- Supports affordable access to quality epilepsy treatments.
Recommended Products
